
Barbara Adamo
Grup de recerca
- Genòmica translacional i teràpies dirigides en tumors sòlids Accredited researcher (R3A)
Publicacions destacades
-
Gene expression profiles of breast cancer metastasis according to organ site
Autors:Referència: Molecular Oncology 2022. -
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT
Autors:Referència: Ebiomedicine 2021. -
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy
Autors:Referència: Clinical Cancer Research 2021. -
COVID-19 pandemic impact in newly diagnosed breast cancer patients (BCP) at a third level hospital
Autors:Referència: Annals Of Oncology 2021. -
Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
Autors:Referència: Annals Of Oncology 2021. -
CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data
Autors:Referència: Annals Of Oncology 2021. -
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
Autors:Referència: Npj Breast Cancer 2021. -
Molecular characterization of advanced breast cancer according to site of metastasis
Autors:Referència: Cancer Research 2021. -
Solti-1502 aRIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer
Autors:Referència: Cancer Research 2021. -
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Autors:Referència: Cancer Treatment Reviews 2020.
Projectes destacats
-
Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes
Investigador/a principal: Aleix Prat AparicioDurada: 15/09/2019 - 14/09/2022 -
Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer
Investigador/a principal: Aleix Prat AparicioFinançador: Instituto de Salud Carlos IIICodi: INT_BCN_Catalyst_18Durada: 01/03/2019 - 28/02/2023 -
Caracterización de los linfocitos T CD8+PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched
Durada: 01/01/2019 - 01/01/2020 -
FIS-ISCIII: Análisis de eficacia de inhibidores cDK4/6 en combinación con tratamiento hormonal en base al subtipo intrínseco y marcadores de inmunidad
Durada: 01/01/2018 -
Convocatòria d'ajuts per donar suport a les activitats dels grups de recerca SGR 2017-2019
Investigador/a principal: FAyaDurada: 01/01/2017 - 01/01/2019